42
Treatment
7.6.1. HF With Mildly Reduced Ejection Fraction
COR LOE
Recommendations
2a B-R 1. In patients with HFmrEF, SGLT2i can be beneficial in
decreasing HF hospitalizations and cardiovascular mortality.
2b B-NR 2. Among patients with current or previous symptomatic
HFmrEF (LVEF 41%–49%), use of evidence-based beta
blockers for HFrEF, ARNi, ACEi or ARB, and MRAs may
be considered to reduce the risk of HF hospitalization and
cardiovascular mortality, particularly among patients with
LVEF on the lower end of this spectrum.
7.6. Mildly Reduced EF (HFmrEF) and Improved EF
(HFimpHF)
Figure 11. Recommendations for Patients With Mildly
Reduced LVEF (41%– 49%)
Evidence-based beta
blockers for HFrEF
(2b)
ACEi, ARB, ARNi
(2b)
MRA
(2b)
Symptomatic HF with
LVEF 41%–49%
SGLT2i
(2a)
Diuretics, as needed
(1)
Medication recommendations for HFmrEF are displayed.
